Abstract
Objectives. To evaluate whether the use of transdermal hormone replacement therapy (HRT), in women within 5 years of menopause compared with women who were postmenopausal for > 5 years, would significantly influence thromboxane B2 levels, plasma viscosity and Doppler flow parameters at the level of the uterine, internal carotid, ophthalmic and bladder wall arteries. Methods. Thirty-five normal-weight (body mass index > 19 and <25 kg/m2) postmenopausal women (age 54.6 ± 3.9 years, mean ± standard deviation) participated in the study and were divided into two groups (Group I: w = 19, time since menopause <5 years; and Group II: n = 16, time since menopause > 5 years). Patients were treated with a continuous estradiol transdermal supplementation and 12-day courses of medroxyprogesterone acetate every 2 months. They were studied at baseline and after 6 months (in the estrogen-only phase of the cycle). Results. Results showed a beneficial effect of hormone substitution after 6 months of therapy. Baseline plasma viscosity was similar in both groups, and decreased significantly after therapy in both Group I (-17.5%) and Group II (-15.6%). Plasma levels of thromboxane B2 were similar at baseline and diminished equally in Group I and Group II (-85.6% and -85.2%, respectively) after treatment. Doppler assessment of the pulsatility index at the level of uterine, internal carotid, ophthalmic and bladder wall arteries showed no differences between groups at baseline and revealed a significant reduction of vascular impedance at the end of the treatment in both groups. Conclusions. Time since menopause does not affect the ootential hemodvnamic benefits of HRT in normal-weight women.
| Original language | English |
|---|---|
| Pages (from-to) | 170-175 |
| Number of pages | 6 |
| Journal | Gynecological Endocrinology |
| Volume | 20 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2005 |
Fingerprint
Keywords
- Doppler
- Hormone replacement therapy
- Plasma viscosity
- Thromboxane
- Time since menopause
ASJC Scopus subject areas
- Endocrinology
- Obstetrics and Gynaecology
Cite this
Time since menopause does not affect plasma viscosity, plasma thromboxane levels and Doppler findings. / Mancini, Fulvia; Persico, Nicola; Regnani, Giorgia; Volpe, Annibale; Battaglia, Cesare; De Aloysio, Domenico.
In: Gynecological Endocrinology, Vol. 20, No. 3, 03.2005, p. 170-175.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Time since menopause does not affect plasma viscosity, plasma thromboxane levels and Doppler findings
AU - Mancini, Fulvia
AU - Persico, Nicola
AU - Regnani, Giorgia
AU - Volpe, Annibale
AU - Battaglia, Cesare
AU - De Aloysio, Domenico
PY - 2005/3
Y1 - 2005/3
N2 - Objectives. To evaluate whether the use of transdermal hormone replacement therapy (HRT), in women within 5 years of menopause compared with women who were postmenopausal for > 5 years, would significantly influence thromboxane B2 levels, plasma viscosity and Doppler flow parameters at the level of the uterine, internal carotid, ophthalmic and bladder wall arteries. Methods. Thirty-five normal-weight (body mass index > 19 and <25 kg/m2) postmenopausal women (age 54.6 ± 3.9 years, mean ± standard deviation) participated in the study and were divided into two groups (Group I: w = 19, time since menopause <5 years; and Group II: n = 16, time since menopause > 5 years). Patients were treated with a continuous estradiol transdermal supplementation and 12-day courses of medroxyprogesterone acetate every 2 months. They were studied at baseline and after 6 months (in the estrogen-only phase of the cycle). Results. Results showed a beneficial effect of hormone substitution after 6 months of therapy. Baseline plasma viscosity was similar in both groups, and decreased significantly after therapy in both Group I (-17.5%) and Group II (-15.6%). Plasma levels of thromboxane B2 were similar at baseline and diminished equally in Group I and Group II (-85.6% and -85.2%, respectively) after treatment. Doppler assessment of the pulsatility index at the level of uterine, internal carotid, ophthalmic and bladder wall arteries showed no differences between groups at baseline and revealed a significant reduction of vascular impedance at the end of the treatment in both groups. Conclusions. Time since menopause does not affect the ootential hemodvnamic benefits of HRT in normal-weight women.
AB - Objectives. To evaluate whether the use of transdermal hormone replacement therapy (HRT), in women within 5 years of menopause compared with women who were postmenopausal for > 5 years, would significantly influence thromboxane B2 levels, plasma viscosity and Doppler flow parameters at the level of the uterine, internal carotid, ophthalmic and bladder wall arteries. Methods. Thirty-five normal-weight (body mass index > 19 and <25 kg/m2) postmenopausal women (age 54.6 ± 3.9 years, mean ± standard deviation) participated in the study and were divided into two groups (Group I: w = 19, time since menopause <5 years; and Group II: n = 16, time since menopause > 5 years). Patients were treated with a continuous estradiol transdermal supplementation and 12-day courses of medroxyprogesterone acetate every 2 months. They were studied at baseline and after 6 months (in the estrogen-only phase of the cycle). Results. Results showed a beneficial effect of hormone substitution after 6 months of therapy. Baseline plasma viscosity was similar in both groups, and decreased significantly after therapy in both Group I (-17.5%) and Group II (-15.6%). Plasma levels of thromboxane B2 were similar at baseline and diminished equally in Group I and Group II (-85.6% and -85.2%, respectively) after treatment. Doppler assessment of the pulsatility index at the level of uterine, internal carotid, ophthalmic and bladder wall arteries showed no differences between groups at baseline and revealed a significant reduction of vascular impedance at the end of the treatment in both groups. Conclusions. Time since menopause does not affect the ootential hemodvnamic benefits of HRT in normal-weight women.
KW - Doppler
KW - Hormone replacement therapy
KW - Plasma viscosity
KW - Thromboxane
KW - Time since menopause
UR - http://www.scopus.com/inward/record.url?scp=18844462482&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=18844462482&partnerID=8YFLogxK
U2 - 10.1080/09513590400027273
DO - 10.1080/09513590400027273
M3 - Article
C2 - 16019357
AN - SCOPUS:18844462482
VL - 20
SP - 170
EP - 175
JO - Gynecological Endocrinology
JF - Gynecological Endocrinology
SN - 0951-3590
IS - 3
ER -